<DOC>
	<DOCNO>NCT02944435</DOCNO>
	<brief_summary>This Phase 1 , randomize , single-dose , 2-way crossover PK comparability study CB-839 administer capsule tablet formulation healthy adult subject .</brief_summary>
	<brief_title>A Comparative , Pharmacokinetic Study CB-839 Capsule Tablet Formulations Healthy Adults</brief_title>
	<detailed_description>A new tablet formulation CB-839 recently develop order enable rapid , automate manufacture CB-839 . Previous study use capsule formulation CB-839 . This study enable PK comparison CB-839 capsule CB-839 tablet . This Phase 1 , comparative , randomize , single-dose , 2-way crossover PK comparability study CB-839 administer capsule tablet formulation healthy adult subject . Serial blood sample PK analysis collect 24 hour period administration CB-839 . All subject monitor safety throughout participation study .</detailed_description>
	<criteria>Healthy , adult , male female , 1855 year age , inclusive , screen . Has use nicotine contain product least 3 mo prior first dose . Body mass index ( BMI ) within 18.0 30.0 kg/m2 , inclusively , screen . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign , ECGs , deem Principal Investigator ( PI ) . For female childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose 14 day follow last dose study drug ( ) use one follow acceptable birth control method : 1 . Nonhormone release intrauterine device place least 3 mo prior first dose study drug either physical ( e.g. , condom , diaphragm ) chemical ( e.g. , spermicide ) barrier method time screen 14 day follow last dose study drug . 2 . A physical barrier method ( e.g. , condom , diaphragm ) chemical barrier method ( e.g. , spermicide ) least 14 day prior first dose study drug 14 day last dose study drug . In addition , female subject childbearing potential advise remain sexually inactive keep birth control method least 14 day follow last dose study drug . For female nonchildbearing potential : must undergo one follow sterilization procedure least 6 mo prior first dose study drug : 1. hysteroscopic sterilization ; 2. bilateral tubal ligation bilateral salpingectomy ; 3. nonsurgical transcervical sterilization ( e.g. , EssureÂ® ) ; 4. hysterectomy ; 5. bilateral oophorectomy ; 6. postmenopausal amenorrhea least 1 year prior first CB839 dose FSH serum level consistent postmenopausal status per PI judgment . A nonvasectomized , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 mo prior study start . A male vasectomized less 4 mo prior study start must follow restriction nonvasectomized male ) . If male , must agree donate sperm dose 90 day last dose . Understands study procedure inform consent form ( ICF ) willing able comply protocol . Subject mentally legally incapacitated significant emotional problem time screen visit expect manifest significant emotional problem conduct study . History presence clinically significant medical psychiatric condition disease opinion PI . History illness , opinion PI , might confound result study pose additional risk subject participation study . History presence alcoholism drug abuse within past 2 year prior screen . History presence hypersensitivity idiosyncratic reaction study drug inactive ingredient ( ) . History presence : 1. liver disease , pancreatic insufficiency intestinal malabsorption ; 2. neuropathy muscle disorder ; 3. seizure ; 4. asthma ; 5. fluid retention ; 6. cardiovascular disease , cardiac arrhythmia , hypertension , cardiovascular thrombotic event , myocardial infarction , stroke ; 7. ulcer disease gastrointestinal bleeding ; 8. renal papillary necrosis renal injury ; 9. exfoliative dermatitis , StevensJohnson syndrome , toxic epidermal necrolysis . Female subject pregnant lactating . Positive urine drug alcohol result screen checkin . Positive urine cotinine screening . Positive result screen HIV type 1 2 , HBsAg , HCV . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . Seated heart rate lower 40 bpm high 99 bpm screening . QTcF interval &gt; 460 msec ( male ) &gt; 480 msec ( female ) deem clinically abnormal PI screening . Estimated creatinine clearance &lt; 90 mL/min screening . Unable refrain anticipates use : 1 . Any nonprescription medication , herbal remedy , vitamin supplement begin 14 day prior first dose study drug throughout study . 2 . Any prescription medication ( include hormonal contraceptive , hormone replacement therapy , lithium ) begin 14 day prior first dose study drug throughout study . 3 . Proton pump inhibitor ( PPIs ) begin 14 day prior first dose study drug throughout study . Has diet incompatible onstudy diet ( opinion PI ) within 28 day prior first dose study drug , throughout study . Donation blood significant blood loss within 56 day prior first dose study drug . Plasma donation within 14 day prior first dose study drug . Participation another clinical trial within 28 day prior first dose study drug . The 28day window derive date last blood collection dosing , whichever later , previous study Day 1 Period 1 current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glutaminase Inhibitor</keyword>
	<keyword>Glutaminase</keyword>
	<keyword>CB-839</keyword>
</DOC>